How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Obstructive Sleep Apnea Therapeutic Device Market
- By Device Type: Continuous Positive Airway Pressure (CPAP) Devices, Bilevel Positive Airway Pressure (BiPAP) Devices, Auto-Adjusting Positive Airway Pressure (APAP) Devices, Oral Appliances, Surgical Implants
- By End User: Hospitals, Sleep Clinics, Home Care Settings, Specialty Clinics
- By Therapy Mode: Fixed Pressure Mode, Auto-Titrating Mode, Bi-Level Pressure Mode
- By Component Type: Masks and Interfaces, Tubing and Connectors, Humidifiers, Pressure Generators
- By Patient Type: Adult Patients, Pediatric Patients
Top segment
Continuous Positive Airway Pressure (CPAP) Devices XX% share · $X,XXXM
In the full report →
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Continuous Positive Airway Pressure (CPAP) Devices leads By Device Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the Obstructive Sleep Apnea Therapeutic Device Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Device Type 5
End User 4
Therapy Mode 3
Component Type 4
Patient Type 2
Companies profiled
ResMed Inc.
Philips Respironics
Fisher & Paykel Healthcare Corporation Limited
Invacare Corporation
DeVilbiss Healthcare LLC
Drive DeVilbiss Healthcare
Somnetics International Inc.
BMC Medical Co. Ltd.
3B Medical Inc.
Apex Medical Corp.
Compumedics Limited
Curative Medical Devices Pvt. Ltd.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →ResMed Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Philips Respironics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Fisher & Paykel Healthcare Corporation Limited
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Invacare Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →DeVilbiss Healthcare LLC
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Drive DeVilbiss Healthcare
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Somnetics International Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →BMC Medical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →3B Medical Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Apex Medical Corp.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Compumedics Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Curative Medical Devices Pvt. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Vyaire Medical Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Lincare Holdings Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Natus Medical Incorporated
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$3,761M by 2033 · 4.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Continuous Positive Airway Pressure (CPAP) Devices46.1
- Bilevel Positive Airway Pressure (BiPAP) Devices10.6
- Auto-Adjusting Positive Airway Pressure (APAP) Devices13.9
- Oral Appliances16.8
- Surgical Implants12.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$855.1M → $1,275M · 5.1%
Europe$596.0M → $816.8M · 4.0%
Asia Pacific$544.2M → $873.3M · 6.1%
Latin America$336.9M → $492.2M · 4.9%
Middle East and Africa$259.1M → $338.3M · 3.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.712026
4.722027
4.732028
4.762029
4.762030
4.772031
4.802032
4.812033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- ResMed Inc.16.4
- Philips Respironics16.5
- Fisher & Paykel Healthcare Corporation Limited5.3
- Invacare Corporation12.1
- DeVilbiss Healthcare LLC14.0
- Drive DeVilbiss Healthcare7.6
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Device Type19.4%
End User23.7%
Therapy Mode18.1%
Component Type8.8%
Patient Type30.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.6
- Europe21.5
- Asia Pacific23.0
- Latin America13.0
- Middle East and Africa8.9
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| ResMed Inc. | 76 | 74 | 87 | 96 | 86 | 79 | 83 |
| Philips Respironics | 93 | 90 | 73 | 69 | 88 | 78 | 82 |
| Fisher & Paykel Healthcare Corporation Limited | 79 | 69 | 65 | 82 | 79 | 72 | 74 |
| Invacare Corporation | 81 | 78 | 81 | 77 | 69 | 62 | 75 |
| DeVilbiss Healthcare LLC | 66 | 63 | 61 | 76 | 69 | 71 | 68 |
| Drive DeVilbiss Healthcare | 47 | 63 | 59 | 67 | 53 | 50 | 57 |
| Somnetics International Inc. | 48 | 45 | 45 | 47 | 65 | 64 | 52 |
| BMC Medical Co. Ltd. | 41 | 57 | 60 | 46 | 53 | 36 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- ResMed Inc.
- Philips Respironics
- Fisher & Paykel Healthcare Corporation Limited
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| ResMed Inc. | ◐ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Philips Respironics | ◐ | ✓ | ◐ | ◐ | ✓ | ◐ |
| Fisher & Paykel Healthcare Corporation Limited | ✓ | − | ◐ | ◐ | ◐ | ◐ |
| Invacare Corporation | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| DeVilbiss Healthcare LLC | ◐ | ◐ | − | ◐ | ✓ | ◐ |
| Drive DeVilbiss Healthcare | ◐ | ◐ | − | − | − | ◐ |
| Somnetics International Inc. | − | ◐ | − | − | ✓ | ◐ |
| BMC Medical Co. Ltd. | − | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1ResMed Inc.83
2Philips Respironics82
3Invacare Corporation75
4Fisher & Paykel Healthcare Corporation Limited74
5DeVilbiss Healthcare LLC68
6Drive DeVilbiss Healthcare57
7Somnetics International Inc.52
8BMC Medical Co. Ltd.49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
ResMed Inc.Philips Respironics
Challenger3
Strong scale, closing on the leaders.
Fisher & Paykel Healthcare Corporation LimitedInvacare CorporationDeVilbiss Healthcare LLC
Contender1
Focused players with pockets of strength.
Drive DeVilbiss Healthcare
Niche2
Specialists in a single segment or region.
Somnetics International Inc.BMC Medical Co. Ltd.
Go-to-market strategy
Land Device Type in North America, then scale across Obstructive Sleep Apnea Therapeutic Device Market — a $242M beachhead inside a $4.21B market.
Beachhead (SOM)$242Mobtainable near-term
Serviceable (SAM)$1.66Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Continuous Positive Airway Pressure (CPAP) Devices
Best fit — highest urgency & budget in Device Type.
Economic buyer76 fit
Bilevel Positive Airway Pressure (BiPAP) Devices
Strong fit — clear ROI and a fast path to value.
End user66 fit
Auto-Adjusting Positive Airway Pressure (APAP) Devices
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Device Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapy Mode
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel28%
Digital / self-serve20%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Device Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Obstructive Sleep Apnea Therapeutic Device Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified24%
Evaluation12%
Closed-won8%
$11.5KCAC
$41KLTV
3.6:1LTV : CAC
< 3 moCAC payback
Investment thesis
Obstructive Sleep Apnea Therapeutic Device Market is a high-growth opportunity — $10.4B by 2033, compounding at 10.4%.
TAM · 2025$4.70Btoday
TAM · 2033$10.4Bforecast
CAGR10.4%2027–2033
Cumulative$64.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.4BTotal addressable market
SAM$3.96BServiceable available market
SOM$852MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.4% CAGR
Demand compounds through 2033, outpacing GDP across Device Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Device Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.4BLarge & growingTAM by 2033 at 10.4% CAGR
$3.96BServiceable nowreachable with today’s model
$852MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$8.08BBear6.8% CAGR
$10.4BBase10.4% CAGR
$13.3BBull13.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Obstructive Sleep Apnea Therapeutic Device Market — a $6.14B market by 2033. Plan: grow share from 8.7% to 14.3%.
Market size · 2033$6.14Btotal addressable
Market CAGR4.4%2027–2033
Target share14.3%from 8.7% today
Revenue ambition$878Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.7% | 14.3% | Behind |
| Revenue | $561M | $878M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 34.9% | 44.0% | Behind |
| Customer retention | 87.9% | 97.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Device Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Device Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $108M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Device Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Sales deck · value proposition
Win the Obstructive Sleep Apnea Therapeutic Device Market conversation — a $4.66B market you can size, segment and defend in minutes.
Market size · 2033$4.66Btotal opportunity
Growth7.4%CAGR to 2033
Addressable buyers954+accounts in scope
Typical ROI5.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Device Type
Goal Grow share in Device Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.2×return on cost, year one
< 3 mopayback period
$51K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
ResMed Inc.Philips RespironicsFisher & Paykel Healthcare Corporation LimitedInvacare CorporationDeVilbiss Healthcare LLCDrive DeVilbiss HealthcareSomnetics International Inc.BMC Medical Co. Ltd.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Obstructive Sleep Apnea Therapeutic Device Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Obstructive Sleep Apnea Therapeutic Device Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Oral Vaccine Market
Market size, share, segmentation and regional forecast.
$14.4B by 2031 · 9.14% CAGR
View reportPolypectomy Snare Market
Market size, share, segmentation and regional forecast.
$9.1B by 2032 · 8.17% CAGR
View reportCoextruded Medical Tube Market
Market size, share, segmentation and regional forecast.
$9.6B by 2033 · 8.60% CAGR
View reportCoronary Guidewire Market
Market size, share, segmentation and regional forecast.
$672M by 2033 · 6.05% CAGR
View reportLight Sources For Endoscope Market
Market size, share, segmentation and regional forecast.
$14.3B by 2033 · 8.79% CAGR
View reportOphthalmic Diagnostic Device Market
Market size, share, segmentation and regional forecast.
$12.2B by 2031 · 4.49% CAGR
View reportOphthalmic Operating Microscope Market
Market size, share, segmentation and regional forecast.
$2.1B by 2031 · 5.80% CAGR
View reportOphthalmic Ultrasound Device Market
Market size, share, segmentation and regional forecast.
$12.6B by 2032 · 3.34% CAGR
View reportOphthalmic Viscoelastic Devices (OVDs) Market
Market size, share, segmentation and regional forecast.
$619M by 2032 · 3.23% CAGR
View reportOphthalmic Viscosurgical Devices (OVD) Market
Market size, share, segmentation and regional forecast.
$12.8B by 2033 · 7.44% CAGR
View reportPeripheral Stent Graft Market
Market size, share, segmentation and regional forecast.
$9.0B by 2033 · 5.79% CAGR
View reportPositron Emission tomography (Pet) Scanners Market
Market size, share, segmentation and regional forecast.
$6.4B by 2031 · 10.40% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.